Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Gains from Investment Securities (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Gains from Investment Securities data on record, last reported at $103000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $103000.0; the TTM value through Sep 2025 reached $621000.0, up 256.42%, while the annual FY2023 figure was -$406000.0, 625.0% down from the prior year.
  • Gains from Investment Securities reached $103000.0 in Q3 2025 per ZNTL's latest filing, down from $531000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $531000.0 in Q2 2025 and bottomed at -$410000.0 in Q4 2023.
  • Average Gains from Investment Securities over 4 years is $17200.0, with a median of -$4500.0 recorded in 2023.
  • Peak YoY movement for Gains from Investment Securities: plummeted 1425.0% in 2024, then skyrocketed 1101.89% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at -$124000.0 in 2022, then tumbled by 230.65% to -$410000.0 in 2023, then soared by 96.83% to -$13000.0 in 2024, then soared by 892.31% to $103000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $103000.0 in Q3 2025, $531000.0 in Q2 2025, and -$13000.0 in Q4 2024.